patients are eligible for treatment for some Failure to build the governance and Ig access to Ig funded conditions. evidence base to governance purposes. under the national support future analysis (NBA) blood arrangements. of treatment This approach is effectiveness and consistent with dosing. approach used by the high cost drugs program. (NBA - 3) Selected Collection of The exclusion The collection of Failure to collect Use Transparent to – Exclusion Exclusion criteria that was exclusion criteria is exclusion criteria as some users of system Criteria Criteria selected by the important to confirm part of the (see security matrix). user as applying that all patients are Authorisation request No disclosure to the patient’s eligible for access to Ig is likely to result in than at level of condition. the national blood patients aggregated arrangements that inappropriately – reports for clinical prescribing practice is receiving Ig treatment governance and Ig compliant with the and non-compliance governance purposes. Criteria for Use. with the Criteria for Use. Exclusion criteria (NBA - 3) have been determined as ineffective and inappropriate use of Ig by using a clinical evidence base
patients are eligible for access to Ig funded under the national blood arrangements. This approach is consistent with approach used by the high cost drugs program. (NBA - 3) treatment for some conditions. (NBA) Failure to build the evidence base to support future analysis of treatment effectiveness and dosing. governance and Ig governance purposes. Selected Exclusion Criteria Collection of Exclusion Criteria The exclusion criteria that was selected by the user as applying to the patient’s condition. The collection of exclusion criteria is important to confirm that all patients are eligible for access to Ig the national blood arrangements – that prescribing practice is compliant with the Criteria for Use. (NBA - 3) Failure to collect exclusion criteria as part of the Authorisation request is likely to result in patients inappropriately receiving Ig treatment and non-compliance with the Criteria for Use. Exclusion criteria have been determined as ineffective and inappropriate use of Ig by using a clinical evidence base Use – Transparent to some users of system (see security matrix). No disclosure than at level of aggregated reports for clinical governance and Ig governance purposes.
ig-gov-and-system-privacy-impact-assesmt-rprt.DOCX